0.40Open0.40Pre Close0 Volume53 Open Interest22.50Strike Price0.00Turnover773.93%IV641.10%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier13DDays to Expiry0.40Extrinsic Value100Contract SizeAmericanOptions Type0.2622Delta0.0725Gamma7.73Leverage Ratio-0.0564Theta0.0001Rho2.03Eff Leverage0.0019Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet